KVUE Stock Recent News

While the calendar was quiet this past week, six IPOs joined the pipeline, two of which we estimate could raise $1 billion or more. Three biotechs filed to raise $100 million.

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce financial results for the fourth quarter and full year ending December 31, 2023, on February 8, 2024.

One of the main themes of 2023 may be relief – that is, relief that we avoided a downcycle – and so it begs the question: why talk about 2024 recession worries? More to the point, why deal with recession stocks?

Some investments just look after themselves. They are “set it and forget it” kind of stocks.

A ruling hurts litigation against Kenvue that alleges a link between prenatal exposure to the company's Tylenol and autism spectrum disorder or ADHD.

Shares of Tylenol maker Kenvue Inc. KVUE, +0.10% gained more than 5% premarket on Tuesday after a federal court judge in New York ruled that plaintiffs' expert testimony will be blocked in a case involving product-liability claims against the manufacturers of Tylenol and generic acetaminophen. Judge Denise Cote of U.S. District Court for the Southern District of New York on Monday granted the defendants' motion to exclude plaintiffs' expert opinions on whether in-utero exposure to acetaminophen could cause children to develop autism spectrum disorder and attention deficit hyperactivity disorder.

In May, Kenvue Inc. (KVUE, Financial) successfully concluded its separation from Johnson & Johnson (JNJ, Financial); however, its stock has experienced a decline about 25% since the completion of this process, likely driven by Investors nervousness about Tylenol litigation. The drop in value appears to be excessive even if the company may have to settle some lawsuits.

The last four years on Wall Street gave investors whiplash. A decade-long bull market came to a screeching halt as the global pandemic brought on one of the worst market crashes in recent memory.

November was the best month for the S&P 500 since July 2022, breaking a three-month losing streak. The stock market appears overvalued after the strong November performance, suggesting a minor pullback may be needed. 3 undervalued dividend stocks to consider buying in December are Kenvue, 3M, and VICI Properties.

The initial public offering (IPO) market has not done well in 2023. The most recent deals have faltered, falling below their IPO pricing on day one or soon after.